Find the right fit for you - faster
Get tailored insights about working at Genevant in one quick step.
Genevant Snapshot
Our Pan-RNA Approach:
Through our industry-leading lipid nanoparticle (LNP) and ligand conjugate delivery platforms, we are able to select and pursue the optimal approach for any given disease. We intend to discover and develop products in-house and form partnerships to build a diverse pipeline of therapeutics across leading RNA modalities, including RNAi, mRNA, and gene editing.
Through our industry-leading lipid nanoparticle (LNP) and ligand conjugate delivery platforms, we are able to select and pursue the optimal approach for any given disease. We intend to discover and develop products in-house and form partnerships to build a diverse pipeline of therapeutics across leading RNA modalities, including RNAi, mRNA, and gene editing.
Genevant Sciences is a biopharmaceutical company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics enabled by proprietary lipid nanoparticle (LNP) and ligand conjugate delivery technologies. Our industry-leading LNP platform has enabled clinical development of the most advanced RNA therapeutics with safety and efficacy evaluated in over 400 patients across multiple programs. We intend to discover and develop products to build a diverse pipeline of therapeutics across leading RNA modalities including RNAi, mRNA, and gene editing.
